Welcome to our dedicated page for Clover Health Investments news (Ticker: CLOV), a resource for investors and traders seeking the latest updates and insights on Clover Health Investments stock.
Clover Health Investments Corp (CLOV) operates at the intersection of health insurance and healthcare technology, making its news coverage particularly relevant for investors tracking the Medicare Advantage sector and artificial intelligence applications in medicine. The company's dual focus on insurance operations and physician enablement software creates distinct news categories worth monitoring.
Earnings announcements from Clover Health reveal performance across both business segments: member enrollment trends in Medicare Advantage plans and enterprise adoption of the Counterpart Assistant technology platform. Quarterly reports disclose medical loss ratios, administrative expenses, and Star Ratings trajectory—metrics that directly impact profitability in the Medicare Advantage business model. The company's technology licensing revenue and partnership announcements with health systems provide insight into market validation for AI-powered clinical tools.
Regulatory developments carry particular significance for Clover Health's business model. Changes to Medicare Advantage payment rates, Star Ratings methodologies, or quality measure definitions announced by CMS can materially affect the company's revenue and competitive position. News about healthcare AI regulations, clinical validation requirements, and reimbursement policies for technology-enabled care management services may impact the Counterpart Health business segment.
Research publications and clinical studies demonstrating outcomes associated with the Counterpart Assistant platform represent important credibility markers for the company's value proposition. Announcements of new health system partnerships, platform capabilities, or geographic expansion indicate commercial traction for the physician enablement strategy. Monitor this page for insights into how Clover Health's technology-first approach to Medicare Advantage evolves in a market dominated by traditional health insurance companies.
Counterpart Health (CLOV) reported 2025 highlights showing scaled clinical impact from its AI physician‑enablement platform, Counterpart Assistant (CA). Key outcomes include a >450% YoY increase in live third‑party customer clinicians, an approximate 1,500 basis point MCR differential for returning Clover members with CA PCPs, and the PPO Medicare Advantage plan achieving the #1 HEDIS score nationwide for a second year.
Retrospective analyses found earlier COPD diagnosis (new members 75% more likely in year one), higher outpatient pulmonology use (+18%), lower all‑cause hospitalizations (CHF −18%; COPD −15%), reduced 30‑day readmissions (CHF −25%; COPD −18%), and 70–89% higher diagnosis rates in high ADI neighborhoods. Product expansions included integrated ambient scribing, natural language chat, proactive visit summaries, and broader enterprise capabilities.
Clover Health (Nasdaq: CLOV) said its CEO Andrew Toy will present at the J.P. Morgan 2026 Healthcare Conference on January 15, 2026 at 11:15 a.m. ET.
A live webcast and a replay of the presentation and Q&A will be available on Clover Health's investor relations website at https://investors.cloverhealth.com/.
Clover Health (Nasdaq: CLOV) announced that its Chief Financial Officer, Peter Kuipers, will present at the 2025 Citi Global Healthcare Conference on Thursday, December 4, 2025 at 11:15 a.m. ET.
A live webcast and replay will be available on Clover Health's investor relations website at https://investors.cloverhealth.com/.
Clover Health (NASDAQ: CLOV) reported Q3 2025 results: Medicare Advantage membership 109,226 (+35% YoY) and Total revenues $496.7M (+50% YoY). Q3 profitability metrics: GAAP net loss $24.4M, Adjusted EBITDA $2.1M, and Adjusted Net income $1.7M. Year-to-date Adjusted EBITDA is $45.0M and Adjusted Net income is $43.7M. Cash and investments totaled $395.9M (down 25.5% YoY). Q3 Insurance BER rose to 93.5% from 82.8% a year earlier; Normalized Insurance BER was 92.4%.
The company raised full‑year 2025 guidance: Avg. MA membership 106k–108k, Insurance revenue $1.85B–$1.88B, Adjusted SG&A $325M–$335M, and Adjusted EBITDA $15M–$30M. Management cited cohort economics, retention, and a favorable 2026 CMS environment as drivers toward improved profitability.
Clover Health (Nasdaq: CLOV) announced that Chelsea Clinton will step down from its Board of Directors effective October 31, 2025 after more than eight years of service, having joined in early 2017.
During her tenure the company grew from serving 30,000 members as a private firm to serving more than 100,000 seniors as a public company across multiple states. Clinton served on the Talent & Compensation Committee and the Nominating and Corporate Governance Committee. Company leaders thanked her for her guidance and emphasized continued commitment to a diverse, experienced Board to support Clover’s mission and growth.
Counterpart Health (Nasdaq: CLOV) released a whitepaper (Oct 30, 2025) showing its Counterpart Assistant (CA) tech helped primary care teams in high Area Deprivation Index neighborhoods detect chronic disease earlier and reduce hospital use.
Key results: diagnosis rates were higher for diabetes (+75%), CKD (+89%), CHF (+89%) and COPD (+70%); CKD detected at average Stage 2 vs 3A; diabetes A1C averaged 6.8% vs 7.1%; inpatient hospitalizations fell -7.6% to -21.2% and 30-day readmissions fell -11.5% to -20.8% across four diseases.
Clover Health (Nasdaq: CLOV) announced that its Chief Financial Officer, Peter Kuipers, will present at the 2025 UBS Global Healthcare Conference on Tuesday, November 11, 2025 at 11:00 a.m. Eastern Time.
A live webcast and replay will be available on Clover Health's investor relations website at https://investors.cloverhealth.com/.
Clover Health (Nasdaq: CLOV) announced its 2026 Medicare Advantage portfolio, preserving a comprehensive PPO lineup with $0 to low monthly premiums and Part B givebacks as Annual Enrollment Period opens Oct 15–Dec 7, 2025. The company says 100% of members will have stable or improved 2026 benefits and plans will be accessible to 5.2 million Medicare-eligible beneficiaries across 203 counties in 5 states. Clover credits its AI-powered Clover Assistant with earlier interventions—doctors start diabetes oral meds ~3 years earlier and diagnose CKD ~1.5 years earlier—and reports 32% YoY MA member growth.
Counterpart Health (CLOV) said its AI-driven HEDIS flywheel again powered Clover Health Medicare Advantage plans to top-tier results and made the platform available to third-party partners on Oct 14, 2025. Clover was the #1 performing PPO for HEDIS clinical quality measures among plans over 2,000 members and the only PPO in the Top 10. The flywheel combines point-of-care Counterpart Assistant prompts, real-time ingestion from 100+ data sources, NLP/LLM abstraction, and AI-augmented documentation closure to raise quality and reduce administrative burden.
Counterpart cites improved benchmark rates for screenings and diabetic eye exams and plans to scale the platform to more partners.
Clover Health (Nasdaq: CLOV) commented on CMS's 2026 Medicare Advantage Star ratings, reporting 3.5 Stars for its PPO MA plans and 4.0 Stars for its HMO MA plan; these ratings affect the 2027 payment year. The company reiterated confidence in driving above‑market membership growth and expanding Adjusted EBITDA profitability through 2027, citing AI‑driven improvements in its Clover Assistant and increased physician adoption. Clover reported H1 2025 revenue +34% and membership +32% year‑over‑year and a PPO HEDIS clinical score of 4.72.
FAQ
What is the current stock price of Clover Health Investments (CLOV)?
What is the market cap of Clover Health Investments (CLOV)?
